

# The effects of a 12-week exercise intervention on respiratory exchange ratio, body composition, thyroid function and lipid metabolism in hypothyroid, obese women

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 08/08/2016	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Andrew C Hutchesson

### Contact details

Consultant in Clinical Chemistry  
Royal Bolton Hospital  
Minerva Road  
Farnworth  
Bolton  
United Kingdom  
BL4 0JR  
+44 (0)1204 390 422  
[Andrew.Hutchesson@boltonh-tr.nwest.nhs.uk](mailto:Andrew.Hutchesson@boltonh-tr.nwest.nhs.uk)

## Additional identifiers

EudraCT/CTIS number

IRAS number

**ClinicalTrials.gov number**

**Secondary identifying numbers**

M0010111344

## **Study information**

### **Scientific Title**

The effects of a 12-week exercise intervention on respiratory exchange ratio, body composition, thyroid function and lipid metabolism in hypothyroid, obese women

### **Study objectives**

Not provided at time of registration

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Not provided at time of registration

### **Study design**

Randomised controlled trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Not specified

### **Study type(s)**

Not Specified

### **Participant information sheet**

### **Health condition(s) or problem(s) studied**

Nutritional, Metabolic, Endocrine: Obesity

### **Interventions**

Patients who appear eligible to the inclusion criteria will be selected from among those having their thyroid function checked, and will be sent a letter via their GP. This letter invites the patient to give consent for the investigator to gain access to her address. If consent is given, the investigator will contact the patient by letter, inviting her to a meeting to discuss the study. Enclosed with this letter will be a patient information sheet and an informed consent form, which the patient will be invited to complete at or within 24 h after the end of the meeting. After recruitment patients randomised to the intervention group will receive a 12-week structured exercise program, supervised by the investigator. Patients in the control group will receive information on 'underactive thyroid' and will have their opportunity to participate in

exercise delayed for 12 weeks. Before and after this period, all subjects will undergo: echocardiography and near infra-red spectrometry, respiratory exchange ratio (RER) rest and exercise, body composition analysis and serum lipid profile and thyroid function measurement. After the second (post-intervention) measurements, all subjects will receive a 3-month membership to the Bolton Excel Cardiogym, where they will have the opportunity to complete an exercise program under qualified gym supervision.

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome measure**

Percentage reduction in body fat.

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

11/03/2002

**Completion date**

01/09/2003

**Eligibility****Key inclusion criteria**

1. Obese (Body Mass Index [BMI] =30.1-40, American College of Sports Medicine [ACSM])
2. Female
3. Sedentary (>90min of moderate physical activity per week)
4. Age 40-50
5. Subclinical hypothyroidism ('mild hypothyroidism'): elevated thyroid stimulating hormone (TSH) 4-10 mU/l but within-normal-range serum and T4 levels (>8 pmol/l)
6. Able to attend exercise sessions

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Female

**Target number of participants**

Not provided at time of registration

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

11/03/2002

**Date of final enrolment**

01/09/2003

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre****Consultant in Clinical Chemistry**

Bolton

United Kingdom

BL4 0JR

## **Sponsor information**

**Organisation**

Department of Health (UK)

**Sponsor details**

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

**Sponsor type**

Government

**Website**

<http://www.doh.gov.uk>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

Bolton Hospitals NHS Trust (UK)

**Results and Publications****Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration